Status: Recruiting
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.
Participants needed: 75
Trial details
Biological sex: FemaleType: ObservationalSponsor: Alexion Pharmaceuticals, Inc.Updated: Apr 16, 2026Locations: 7Duration: 21 Months
Eligibility criteria
Female participant must have a medically confirmed qualifying pregnancy (prospec... [+6]
Participants who are unable to provide consent or assent (as locally appropriate...